[Frontiers in Bioscience 3, d1192-1208, December 1, 1998]
Reprints
PubMed
CAVEAT LECTOR



Table of Conents
Previous Section Next Section

PAPILLOMAVIRUS VACCINES

Margaret F. Duggan-Keen, Michael D. Brown, Simon N. Stacey and Peter L. Stern

Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX , United Kingdom

Received 7/21/98 Accepted 9/22/98

TABLE OF CONTENTS

1. Abstract
2. Introduction: Why HPV vaccines?
3. Issues in vaccine design:
3.1. HPV life cycle
3.2. Target antigens for prophylaxis or therapy
3.3. Natural immunity against HPV
4. Candidate vaccines
4.1. Animal models
4.2. Virus like particles (VLPs)
4.3. Proteins
4.4. Peptides
4.5. Viral vectors
4.6. DNA
4.7. Bacterial vectors
4.8. Dendritic cells
5. Vaccine clinical trial parameters
5.1. Evaluation of vaccine clinical efficacy
5.2. Cost and ease of implementation
5.3. Why might HPV vaccines not work?
6. Summary
7. Acknowledgement
8. References
9. Entire manuscript

Key words: Human Papillomaviruses, Cervical Cancer, Viral Vaccines, Cancer Vaccines, Review, Cervical Intraepithelial Neoplasia, Immunotherapy

Search OMIM (Online Mendelian Inheritance in Man) to find related articles
This form requires a WWW Client such as Netscape, XMosaic, Lynx that supports fill-in forms.

Enter one or more search keywords:

To Search all fields, leave the following boxes unchecked. To narrow your search to certain specific fields, check the boxes next to those fields' names. SeeQuery Help for other ways to search. Title: OMIM Number: Allelic Variants: Text: References: Clinical Synopsis: Gene Map Disorder: Contributors: See only records which have been changed in the past Display at most